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Abstract
Incorporation of the envelope (Env) glycoprotein into budding virions is a key step in the replication cycle of lentiviruses. Previously, we provided
genetic and biochemical evidence indicating that Env packaging into simian immunodeficiency virus (SIV) particles ismediated by the association of the
Env cytoplasmic domain (CD) with the matrix (MA) domain of Gag. In this study, we developed an in vitro binding assay that, based on recombinant
proteins expressed in bacteria, allowed us to demonstrate the physical interaction between the SIV Env CD and the MA in the absence of other viral or
cellular proteins.We show that this association is blocked bymutations in each of the interacting domains that have been reported to interfere in vivowith
the incorporation of Env intoSIV virions.Moreover,we determined that the binding of SIVMA to the EnvCD is saturablewith a dissociation constant of
7×10−7 M. Interestingly, the SIVMA is capable of specifically interacting in vitro with the human immunodeficiency virus type 1 Env CD, but not with
that of the distantly related feline immunodeficiency virus. Our results strongly support the notion that the association between the SIVMA and Env CD
plays a central role in the process of SIV Env incorporation into Gag-made particles.
© 2008 Elsevier Inc. All rights reserved.Keywords: Simian immunodeficiency virus; Matrix protein; Envelope glycoprotein cytoplasmic domain; Virus assemblyIntroduction
The retroviral Gag proteins bear all the structural elements
necessary for particle assembly (Hunter, 1994). In the case of the
primate lentiviruses human and simian immunodeficiency
viruses (HIV and SIV, respectively), Gag is first synthesized as
a polyprotein precursor which, subsequent to virus budding, is
proteolytically processed by the viral protease into the matrix
(MA), capsid (CA), nucleocapsid and p6 proteins, as well as the
p2 and p1 spacer peptides (Henderson et al., 1992). In addition to
Gag processing, the formation of infectious lentivirus particles
requires the incorporation of the viral envelope (Env) glycopro-
tein into the budding virions. The functional Env complex,
composed of the surface (SU; gp120) and the transmembrane
(TM; gp41) glycoproteins, is responsible for the specific binding
of virions to the cellular CD4 and chemokine receptors, which⁎ Corresponding author. Fax: +54 11 4963 9278.
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0042-6822/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2008.01.015triggers the fusion of the viral and target cell membranes and thus
mediates virus entry (Chan and Kim, 1998).
The MA domain of the SIV Gag precursor has been shown to
be implicated in a number of key roles during the virus life cycle:
it provides the primary determinants for the proper targeting and
association of the Gag precursor with the plasmamembrane and is
necessary for viral particle assembly as well (González and Af-
franchino, 1995, 1998; González et al., 1993, 1996). In addition,
the SIV MA protein appears to be involved in the process of Env
incorporation into virions. In this regard, we have provided
genetic and biochemical evidence supporting the notion that the
interaction between the SIV TM cytoplasmic region, which is
164-amino acid long, and the MA domain of Gag mediates the
packaging of Env into SIV virions. Indeed, we have previ-
ously shown that truncations or in-frame deletions affecting the
C-terminus of the SIV TM cytoplasmic domain (CD) inhibit
Env incorporation into virions (Celma et al., 2001; Manrique
et al., 2001), and that removal of the C-terminal 20 amino acids
of the SIV TM protein is sufficient to impair Env packaging
Fig. 1. In vitro binding assay for the interaction between the SIVMA and the Env
CD. (A) The wild-type (CDSIV) or mutant (CD104) SIV Env CD polypeptides
were expressed as GST fusion proteins, immobilized on glutathione-Sepharose
beads, resolved by SDS-gel electrophoresis on a 10% polyacrylamide gel and
stained with Coomassie G-250. Equivalent amounts of immobilized GST, GST-
CDSIV, or GST-CD104 were incubated with recombinant wild-type SIVMA (B),
or the mutant MA proteins L31E (C), R22L/G24L (D), or R22L/G24L/L31E
(E) as described in Materials and methods. The protein complexes coupled to the
resin were resolved by SDS-PAGE (12% polyacrylamide gel) and detected by
Western blotting using the monoclonal antibody KK59 (B), or a polyclonal
antiserum specific for the SIVMA (C, D and E). INPUT: As control, one-tenth of
the total amount of MA protein used in each binding reaction was loaded on each
gel. Themobilities of the wild-type andmutantMAproteins are shown, as are the
positions of the molecular weight standards.
274 J.M. Manrique et al. / Virology 374 (2008) 273–279into particles (Manrique et al., 2001). Likewise, certain
mutations within the SIV MA-coding region block Env
incorporation into particles (González et al., 1996; Manrique
et al., 2003). Interestingly, that an association between the MA
and TM proteins is necessary for Env incorporation into virions
has also been shown for HIV-1 (Dorfman et al., 1994; Freed and
Martin, 1995, 1996; Kalia et al., 2003; Murakami and Freed,
2000; Wyma et al., 2000; Yu et al., 1992). Of note, we have
demonstrated that mutations within the SIV MA region span-
ning the N-terminal α-helices H1 and H2 confer a differential
ability to Gag to associate with the Env glycoprotein, thereby
modulating either negatively or positively the levels at which
Env is incorporated into virions (Manrique et al., 2003). Based
on these precedents, and given the relevance of Env
incorporation into virions to virus infectivity, we developed
an in vitro association assay that allowed us to demonstrate the
physical interaction between the SIVMA and the TMCD in the
absence of other viral or cellular proteins.
Results
Establishment of an in vitro assay for the association between
the SIV MA and the Env cytoplasmic domain
To study the interaction between the MA protein and the Env
CD of SIV, the latter was expressed in Escherichia coli as
fusion with Schistosoma japonicum glutathione S-transferase
(GST) (Fig. 1A), immobilized onto a glutathione-coupled Se-
pharose resin, and used as bait in GST pull-down assays. As
prey protein, we used recombinant SIV MA purified from
E. coli extracts as described in Materials and methods. As
shown in Fig. 1B, the SIV MA protein bound in a specific
manner to the GST-CDSIV fusion protein, but not to beads
coated with GST alone, indicating that the SIV MA and the Env
CD are capable of establishing a direct physical interaction.
We have previously shown that mutant CD104, a mutant SIV
Env glycoprotein lacking the C-terminal 60 residues, is not
incorporated into Gag particles (Manrique et al., 2001). Interes-
tingly, this mutant Env CD was unable to interact with the SIV
MA in the pull-down assays (Fig. 1B). Moreover, an SIV MA
protein carrying the L31E single amino acid substitution did not
associate in vitro with the GST-CDSIV protein (Fig. 1C), which
is in agreement with the Env incorporation-defective phenotype
exhibited by the virus bearing this single point mutation in the
MA-coding region (Manrique et al., 2003). By contrast, a spe-
cific interaction between the GST-CDSIV protein and the mutant
R22L/G24L MA protein was observed (Fig. 1D). Furthermore,
introduction of the R22L/G24L mutation in the context of the
mutant L31E MA protein partially restored SIV Env CD-MA
association (Fig. 1E). These results are in line with our previous
data reporting that the SIV Env glycoprotein is efficiently in-
corporated into the R22L/G24LMAmutant virions and that this
double amino acid substitution in SIV MA can substantially
compensate for the Env incorporation and infectivity defects
exhibited by the L31E mutant (Manrique et al., 2003).
The assays described above are based on the elution in
Laemmli buffer of the MA protein bound to the GST-CDSIVbeads. To provide further evidence for the specificity of this
assay, the GST-CDSIV-coated beads were first incubated with the
MA protein and then treated in parallel with thrombin in phos-
phate-buffered saline (PBS) or with PBS alone. Subsequently,
both samples were centrifuged to sediment the resin, and the
presence of viral proteins in the supernatants was analyzed by
Western blotting. Since there is a thrombin recognition site bet-
ween the GST and CD moieties in the fusion protein, treatment
with thrombin would be expected to release the CD-MA protein
complexes. As shown in Fig. 2, both the MA and the Env CD
were detected in the supernatant of the binding reaction subjected
to thrombin treatment, whereas neither of these proteins were
observed in the supernatant fraction obtained after incubation of
the resin-coupled proteins in PBS. This result therefore confirms
that in these pull-down assays the MA protein specifically inter-
acts with the CD moiety of the GST-CDSIV fusion protein im-
mobilized on the glutathione resin.
Determination of the binding constant for the interaction
between the SIV MA and the Env cytoplasmic domain
The interaction between two proteins is governed by the
binding constant (Kd) which reflects the strength of their
Fig. 2. Elution of the SIV MA-CD complexes by thrombin treatment. Equivalent
amounts of the GST-CDSIV fusion protein were coupled to glutathione-Sepharose
beads and incubated with recombinant SIV MA. After extensive washings, the
beadswere incubated for 3 h either with PBS alone (−) or with PBS containing 0.25
U thrombin (+). The proteins in the supernatants resulting from resin centrifugation
were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The
membranewas first incubatedwith the anti-SIVMApolyclonal serum (Left panel),
and then reprobed with the antiserum specific for the SIV Env CD (Right panel).
The mobilities of theMA and Env CD polypeptides are shown, as are the positions
of the molecular weight standards.
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to estimate binding constants (Phizicky and Fields, 1995). The
binding reaction is performed using various concentrations of
the immobilized protein that are in excess over that of its ligand.
Under these experimental conditions, the minimal concentration
of the immobilized protein that retains 50% of the ligand cor-
responds to the Kd value (see Materials and methods; Formosa
et al., 1991; Mason and Lis, 1997; Phizicky and Fields, 1995).
We therefore made use of this method to determine the Kd of
the SIV MA-Env CD interaction. In these experiments, increa-
sing amounts of the GST-CDSIV fusion protein immobilized on
the glutathione-Sepharose resin were incubated with a constant
and limiting amount of the SIVMA protein followed by a single
washing. The percentage of bound SIV MAwas determined by
Western blotting as described in Materials and methods. The
binding curve obtained with the data from three independent
experiments allowed us to estimate that the SIV MA interacts in
vitro with the Env CD with a Kd of 7×10−7 M (Fig. 3).Fig. 3. Saturation curve for the interaction between the SIV MA and the Env CD.
Increasing amounts of the GST-CDSIV fusion protein coupled to glutathione-
Sepharose beads were incubated with a fixed and limiting concentration of the SIV
MA, and the amount of bound MA for each point was determined as described in
Materials and methods.Binding of the SIV MA protein to the Env cytoplasmic domain
of related lentiviruses
The SIV MA protein shares only 50% amino acid sequence
identity with that of HIV-1. However, X-ray crystallographic
data indicate that these proteins exhibit a high degree of struc-
tural similarity (Hill et al., 1996; Rao et al., 1995).
We therefore sought to investigate whether the SIV MAwas
capable of interacting with the CDof the HIV-1 Env glycoprotein.
For comparison, we also tested the potential association of the
SIV MAwith the Env CD of a distantly related lentivirus such as
feline immunodeficiency virus (FIV), which is unusually short
(approximately 53 amino acids) compared to its primate lentiviral
counterparts (Celma et al., 2007). The CDs of the HIV-1 and FIV
Env glycoproteins were expressed in E. coli as GST fusion
proteins (Fig. 4A), immobilized onto glutathione-Sepharose
beads, and incubated with the SIV MA protein. Fig. 4B shows
that the amount of SIV MA bound to the HIV-1 Env CD was
similar to that detected when the SIV Env CD was used as bait
protein in the pull-down assays. By contrast, the FIVEnvCDonlyFig. 4. In vitro binding assay to test the interaction of the SIVMAwith the EnvCDs
of HIV-1 and FIV. (A) The CDs of the HIV-1 and FIV Env proteins were expressed
as GST fusion proteins in E. coli, purified by affinity chromatography, resolved by
SDS-gel electrophoresis on 10% polyacrylamide gels, and visualized by
Coomassie G-250 staining. (B) Equivalent amounts of GST, GST-CDSIV, GST-
CDHIV, and GST-CDFIV immobilized on gluathione-Sepharose beads were incu-
bated with recombinant SIV MA. Protein complexes resulting from the binding
reactions were resolved by SDS-PAGE (12% polyacrylamide gel) and the bound
MA in each case was detected by Western blotting using a polyclonal antiserum
specific for the SIVMA. INPUT: one-tenth of the total amount of SIVMA protein
used in the binding reactionwas loaded on the gel. (C) In vitro association of HIV-1
MA with SIV and HIV-1 Env CDs. Biotinylated HIV-1 MAwas incubated with
equivalent amounts of purified GST, GST-CDSIV, and GST-CDHIV as decribed in
Materials and methods. HIV-1MA binding was analyzed byWestern blotting with
horseradish peroxidase-conjugated streptavidin. INPUT: one-tenth of the total
amount of biotinylated HIV-1MA protein used in the pull-down assays was run in
the gel. (D) Effect of TIP47 onHIV-1MA-EnvCDassociation. BiotinylatedHIV-1
MA was incubated with equivalent amouints of GST and GST-CDHIV in the
absence (−) or presence (+) of recombinant His-TIP47. Binding of HIV-1 MA and
TIP47 in the pull-down assays was analyzed byWestern blotting with horseradish
peroxidase-conjugated streptavidin, or with an antibody specific for penta-His,
respectively. As controls, samples corresponding to one-tenth of the total amount
of HIV-1 MA and His-TIP47 proteins used in the binding reaction were loaded on
the gel.
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that the SIV MA is capable of establishing a specific interaction
with the HIV-1 Env CD, but not with that of FIV. Based on these
results, we next tested the HIV-1MA for its ability to interact with
the SIV Env CD. As shown in Fig. 4C, the HIV-1 MA bound to
the SIV Env CD at levels comparable to those detected when the
GST-CDHIV fusion protein was coupled to the resin. Recently, the
cellular protein TIP47 (Tail-interacting protein of 47 kDa) has
been shown to mediate the association between the HIV-1 Gag
and Env proteins during particle assembly (Lopez-Vergès et al.,
2006). We therefore investigated whether the addition of human
TIP47 to the binding reaction had any effect on the in vitro
association of the HIV-1 MA with the Env CD. Under our
experimental conditions, recombinant His-TIP47 specifically
interacted with the GST-CDHIV fusion; however, the presence
of TIP47 did not enhance binding of the HIV-1MA to the EnvCD
(Fig. 4D). Furthermore, we found that addition of TIP47 in our
pull-down assays had no effect on the in vitro interaction between
the SIV MA and Env CD proteins (data not shown).
Discussion
Our previous mutagenesis studies of the SIV Gag and Env
proteins strongly supported the notion that the process of SIV
Env incorporation into virions is mediated by MA-Env CD
interactions (Celma et al., 2001; Manrique et al., 2001, 2003).
However, the physical interaction between these viral protein
domains remained to be demonstrated. To this end, we deve-
loped an in vitro system that, based on recombinant proteins
expressed in E. coli, allowed us to analyze the association
between the SIV MA and the Env CD. Our pull-down assays
show that the SIV MA is capable of establishing a specific
interaction with the Env CD in the absence of other viral or
cellular proteins. Moreover, this association is blocked in vitro
by mutations in either the MA (mutation L31E) or Env CD
(mutation CD104) that have been shown to interfere in vivo
with Env packaging into virions (Manrique et al., 2001, 2003).
Estimation by protein affinity chromatography of the binding
constant for the SIV MA-Env CD interaction yielded a Kd of
7×10−7 M. Interestingly, binding constants of a similar order of
magnitude have been reported for complexes established by
other primate lentiviral proteins. Indeed, HIV-1 gp120 associ-
ates with soluble CD4 with a Kd of 4.29×10−7 M (Biorn et al.,
2004) and with CXCR4 with a Kd of 5.06×10−7 M (Hoffman
et al., 2000). Binding of SIVmac gp130 to CD4 has been to
shown to occur with a Kd of 3.5×10−7 M (Ivey-Hoyle et al.,
1991). In addition, a Kd of 8.7×10−7 M has been determined
for the HIV-1 Nef-CD4 cytoplasmic domain interaction (Preus-
ser et al., 2001). By contrast, HIV-1 Vpr binds to the p6 domain
of Gag with lower affinity (Kd of 7.5×10−5 M) (Jenkins et al.,
2001).
The association between the MA domain of Gag and the Env
CD has also been investigated for HIV-1. In this regard, it has
previously been reported that the HIV-1 Env CD produced in
E. coli as a fusion protein with GST captures recombinant HIV-1
MA expressed either in bacteria or in COS-1 cells (Cosson,
1996). In this regard, we found that recombinant HIV-1 MA iscapable of interacting with both HIV-1 and SIV Env CDs.
However, under our experimental conditions this association
does not appear to be either dependent on or enhanced by the
addition of TIP47 to the binding reaction. This could be ex-
plained by the fact that recombinant TIP47 preparations may
contain only a small proportion of active molecules (Krise et al.,
2000). On the other hand, our finding that the in vitro interaction
between the SIV MA and Env CD proteins proceeds in the
absence of TIP47 is consistent with the fact that one of the
regions in the HIV-1 MA (DRWE, residues 14–17) that have
been reported to be necessary for TIP47 interaction (Lopez-
Vergès et al., 2006) is not conserved in SIVor HIV-2. However,
we cannot rule out the possibility that, in vivo, cellular factors
(including TIP47) may modulate the process of SIV Env incor-
poration into virions. Further experiments will be necessary to
address this issue. That equivalent domains of HIV-1 and SIV
Gag polyproteins exhibit different properties is not without pre-
cedent: HIV-1 CA protein binds to cyclophilin Awhereas that of
SIV fails to associate with this cellular protein (Braaten et al.,
1996).
An interesting observation stemming from our in vitro
binding assays is that the SIV MA is able to associate with the
HIV-1 Env CD but not with that of the distantly related
lentivirus FIV. Our evidence that the SIV MA interacts with the
HIV-1 Env CD is in agreement with the fact that construction of
SIV/HIV chimeric viruses (SHIVs) expressing SIV Gag and
HIV-1 Env proteins results in replication-competent viruses that
are pathogenic in monkeys (Li et al., 1992).
An important consequence of the interaction between the MA
domain of Gag and the Env CD is that it not only ensures the
incorporation of Env into virions during particle assembly, and,
thus, virus infectivity, but also appears to be necessary for
regulating the biological functions of each of the interacting
partners. Several lines of evidence support this notion: (i) the high
endocytosis rate of HIV-1 Env is drastically reduced when coex-
pressed with Gag, thus favoring Env incorporation into particles
(Egan et al., 1996); (ii) Gag-Env interaction in HIV-1 immature
particles blocks Env fusogenic activity which is restored upon
Gag processing and formation ofmature virions (Murakami et al.,
2004; Wyma et al., 2004), a mechanism that appears to prevent
entry of immature virions into cells; (iii) Gag-Env interaction has
been shown to be necessary for Env association with lipid rafts,
which constitute the plasma membrane sites where virus as-
sembly takes place (Bhattacharya et al., 2004).
In summary, our GST-pull-down assays using recombinant
SIVMA and Env CD proteins, together with our previous in vivo
genetic and biochemical studies, suggest that the interaction
between these viral protein domains is a necessary step in the
process of SIV Env incorporation into virions.
Materials and methods
Cloning, expression and purification of recombinant proteins
The coding regions for the wild-type and mutant L31E,
R22L/G24L, and R22L/G24L/L31E SIV MA proteins were
PCR amplified from the SIVSMM PBj1.9 or mutant proviral
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triction sites at the 5′ and 3′ ends of the DNA products,
respectively. The open reading frame for the HIV-1 pNL4-3 MA
protein was obtained using the same strategy. The NcoI/SmaI-
digested fragments were cloned into the corresponding sites of
the pTYB4 plasmid vector of the IMPACT T7 System (Intein-
Mediated Purification with an Affinity Chitin-binding Tag, New
England Biolabs). This system allowed the expression of the
MA open reading frames as fusions with intein, the protein
splicing element from the Saccharomyces cerevisiae WMA1
gene (Chong et al., 1997), together with the chitin-binding
domain. The coding sequences for the Env CD of SIVSMM
PBj1.9, SIV mutant CD104 (Manrique et al, 2001), HIV-1
pNL4-3, and FIV-14 Petaluma, were obtained by PCR ampli-
fication of the corresponding proviral DNAs using 5′ and 3′
primers that introduce unique BamHI and EcoRI restriction
sites, respectively. The amplified DNAs were cloned into the
BamHI and EcoRI sites of the pGEX-2T plasmid (GE Life
Sciences) for the in-frame translation with GST. The recombi-
nant proteins were produced in E. coli BL21 (for the pTYB-
derived clones) or DH5α (for the pGEX-2T-derived clones)
strains by induction with 1 mM isopropyl-β-D-thiogalactopyr-
anoside essentially as we have previously described (Manrique
et al., 2004). After induction, bacterial extracts for the puri-
fication of the recombinant MA proteins were obtained by
sonication in TNE buffer (20 mM Tris–HCl [pH 8.0]; 500 mM
NaCl; 0.1 mM EDTA) containing 0.5% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 1 mM phe-
nylmethylsulfonyl fluoride (PMSF) and 10 μg/ml aprotinin.
Insoluble material was removed by centrifugation for 10 min
at 16,000 ×g, and the supernatants containing the intein/chitin-
binding domain-taggedMAproteinsweremixedwith a 50% (v/v)
slurry of chitin beads and incubated for 60min at 4 °C. Beadswere
washed with TNE buffer and recombinant MA proteins were
released by incubating the beads in TNE containing 30 mM
dithiothreitol overnight at 4 °C. To produce recombinant
biotinylated HIV-1 MA, the resin-coupled fusion protein was
biotinylated at the C-terminus by intein-mediated protein ligation
in the presence of the synthetic Bio-P1 peptide (New England
Biolabs) under the conditions recommended by the manufacturer.
Supernatants containing the eluted recombinantMAproteinswere
stored at −80 °C until further use. The GST and GST-CD fusion
proteins were purified from bacterial lysates as described
previously (Manrique et al., 2004). The cDNA for human TIP47
was amplified by reverse transcriptase-PCR frommRNA purified
from293Tcells by using specific primers and cloned into theKpnI
and BamHI sites of the pET-30b (+) plasmid (Novagen). Recom-
binant histidine-tagged TIP47 was purified from E. coli BL21
lysates by immobilized metal ion adsorption chromatography
according to the manufacturer's protocol (His Microspin Puri-
fication Module; GE Life Sciences) and stored at −80 °C in the
presence of 10% glycerol (Krise et al., 2000). Protein concentra-
tions were estimated by comparison to known amounts of stan-
dard bovine serum albumin (BSA) on sodium dodecyl sulfate
(SDS)-polyacrylamide gels stained with Coomassie G-250
SimplyBlue Safe Stain (Invitrogen). Quantitation of the amount
of protein on gels was performed by densitometry using theGelWorks 1D software (UVP GDS 8000; Ultra Violet Products,
Ltd.).
In vitro binding assays
Six micrograms of GST or GST-CD fusion proteins were
pre-bound to glutathione-Sepharose 4B (GE Life Sciences) and
incubated with 500 ng purified wild-type or mutant SIV MA
proteins in 100 μl PBS containing 0.5% CHAPS, 1% BSA,
1 mM PMSF and 10 μg/ml aprotinin for 2 h at 4 °C. Binding of
TIP47 and MA to Env CD was analyzed by incubating the
immobilized GST-CD fusion proteins with 2 μg His-TIP47 and
850 ng biotinylated HIV-1 MA in 100 μl PBS containing 0.01%
Triton X-100, 1% BSA, 1 mM PMSF and 10 μg/ml aprotinin
overnight at 4 °C. Beads were washed 6 times with 40 bed
volumes of the corresponding binding buffer. The protein com-
plexes were eluted from the glutathione resin by resuspending
the beads in Laemmli sample buffer, resolved by SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE), and blotted onto
nitrocellulose membranes. Alternatively, in the case of elution
of the protein complexes by thrombin treatment, the resin was
resuspended in PBS containing 0.25 cleavage units of thrombin
and incubated for 3 h at 25 °C. The Sepharose beads were
pelleted by low-speed centrifugation and the eluate was resol-
ved by SDS-PAGE. The presence of the wild-type or SIV
mutant MA proteins in the eluted protein complexes was
analyzed by Western blotting using the SIV MA-specific KK59
monoclonal antibody (NIH Research and Reference Reagent
Program) or a mouse anti-SIV MA polyclonal serum, respec-
tively, and horseradish peroxidase-conjugated anti-mouse im-
munoglobulin (GE Life Sciences) as secondary antibody. The
antisera directed against the SIV MA or the SIV Env CD were
obtained in our laboratory by immunization of mice with the
purified bacterially expressed polypeptides essentially as we
have recently described (Celma et al., 2007). Biotinylated HIV-
1 MAwas detected by using horseradish peroxidase-conjugated
streptavidin (GE Life Sciences). Detection of His-TIP47 in the
binding assays was performed by Western blotting using a
horseradish peroxidase-conjugated antibody specific for penta-
His (QIAGEN). Western blots were developed with an en-
hanced chemiluminescence and chemifluorescence assay (ECL
Plus Reagent, GE Life Sciences).
Dissociation constant determination
Determination of the Kd for the SIV MA-Env CD interaction
was based on themethod described byPhizicky and Fields (1995).
Estimation of the binding constant for the interaction between a
given protein (P) and its ligand (L) is governed by the following
equationwhich refers to the fraction of L bound to protein P: [PL]/
[LTOTAL]=[PFREE] / [PFREE]+Kd. If the concentration of protein
P is in great excess over that of the ligand, [PFREE]≈ [PTOTAL].
Then, [PL] / [LTOTAL]= [PTOTAL] / [PTOTAL]+Kd. When 50%
of the ligand is bound to protein P ([PL] / [LTOTAL]=0.5), then
[PTOTAL] / [PTOTAL]+Kd=0.5, and, therefore, [PTOTAL]=Kd. For
the experimental determination of theKd of the SIVMA-Env CD
interaction, increasing concentrations (0–216 pmol) of GST-
278 J.M. Manrique et al. / Virology 374 (2008) 273–279CDSIV coupled to the glutathione-Sepharose resin were incu-
bated with 50 ng recombinant SIV MA in 100 μl Binding Buffer
for 2 h at 4 °C. Beads were then collected by centrifugation,
washed oncewith 50 bed volumes PBS containing 0.1%BSA and
0.5% CHAPS, and the bound proteins were resolved by SDS-
PAGE, and subsequently transferred to a nitrocellulose mem-
brane. The percentage of SIVMA recovery for each concentration
of GST-CDSIV was determined by comparing to known amounts
of SIV MA by Western blotting with the KK59 monoclonal
antibody. Quantitation was performed as we have previously
described (Manrique et al., 2003).
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